$34.10+1.71 (+5.28%)
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Harmony Biosciences Holdings, Inc. in the Healthcare sector is trading at $34.10. Wall Street consensus targets $44.36 (11 analysts), implying a +30.1% move over the next 12 months. The stock is currently 17% below its 52-week high of $40.87, remaining 5.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule wi...
Reviewing past stock picks is an essential part of the investment process. Harmony Biosciences which Todd Chanko reviewed in March. Watch Doug discuss recent stock picks, provide his input on the current market environment—and take your questions.
We just covered the 10 Best Stocks to Buy Right Now According to AI and Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) ranks 10th on this list. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company focused on developing therapies for patients suffering from rare neurological diseases. The flagship commercial product is WAKIX (pitolisant), a first-in-class […]
Harmony Biosciences develops therapies for rare neurological disorders, with WAKIX addressing excessive sleepiness in narcolepsy patients.
The most recent earnings report from Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) was disappointing for...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best healthcare stocks to buy for the long term. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced financial results for fiscal Q1 2026 on May 7, reporting net product revenue of $215.4 million for the quarter, delivering 17% year‑over‑year growth, and on track for full year 2026 net […]